Business Wire

Endospan Announces Positive 30-Day Data from TRIOMPHE FDA Clinical Study of NEXUS® Aortic Arch Stent-Graft

TEL AVIV, Israel--(BUSINESS WIRE)--Endospan today announced the presentation of 30-day results of the statistical Dissection Primary Arm from the TRIOMPHE Investigational Device Exemption (IDE) ...
Morningstar

Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System

Endospan's NEXUS branched endovascular stent graft system shown to effectively treat aortic arch disease, including chronic aortic dissections ATLANTA, April 7, 2026 /PRNewswire/ -- Artivion, Inc.
Morningstar

Endospan Receives FDA Approval for the NEXUS® Aortic Arch Stent Graft System

FDA approval was supported by the one-year results of the TRIOMPHE Investigational Device Exemption (IDE) Study evaluating the NEXUS® System shown to effectively treat aortic arch disease, including ...
Business Wire

Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS ® Aortic Arch System

HERZLIYA, Israel--(BUSINESS WIRE)--Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction to acquire ...